Journal
CURRENT TOPICS IN MEDICINAL CHEMISTRY
Volume 13, Issue 22, Pages 2808-2849Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/15680266113136660201
Keywords
Tuberculosis; chemistry; medicinal chemistry; novel compounds; clinical trial; Mycobacterium tuberculosis
Categories
Funding
- National Counsel of Technological and Scientific Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq)
- Rio de Janeiro Research Foundation (Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJ)
- Oswaldo Cruz Foundation (Fundacao Oswaldo Cruz - FIOCRUZ)
- Drug Technology Institute (Instituto de Tecnologia em Farmacos-Famanguinhos)
- Federal University of Rio de Janeiro (Universidade Federal do Rio de Janeiro - UFRJ)
Ask authors/readers for more resources
Tuberculosis (TB) is a serious public health issue, particularly in underdeveloped and developing countries. Furthermore the first-line anti-TB treatments were established over 40 years ago, multidrug-resistant Mycobacterium tuberculosis strains have been developed and the risk of coinfection with AIDS virus has highlighted this disease as a global emergency. The urgent need for more effective treatments against multidrug-resistant strains compatible with anti-AIDS drugs has prompted industries, governments and non-governmental agencies to pursue new drugs. In this study, we update the portfolio listed at Stop TB Partnership, present the biological activities as well as structure-activity relationship for these drugs and thoroughly discuss the synthetic methodologies used to produce these drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
